Developer docs
API playgroundTry for free, no card

Search company profiles

Spark Neuro

Full company profile

uuid0000x54

Namestring
Spark Neuro
Legal namestring
SPARK Neuro
Websiteurl
sparkneuro.com
Company typeenum
Private
Founded yearint
2017
Descriptiontext

SPARK Neuro is a New York-based neuroscience company founded in 2017 that has pivoted from its original neuromarketing focus to clinical dementia diagnosis. Its core product, SPARK Scan, is an FDA-cleared EEG-based screening tool that uses a proprietary machine-learning platform built on patent-pending Fractal Dimension Distributions (FDD) signal processing to detect and differentiate between dementia-causing diseases. The technology achieves 90%+ disease classification accuracy, 82% screening true positive rate, 96% accuracy in detecting Alzheimer's, and 80%+ accuracy in differentiating between Alzheimer's, Parkinson's, and Dementia with Lewy Bodies. SPARK Neuro has accumulated 900+ EEG datasets since 2021, secured 2 FDA clearances, and supported 5 clinical trials as of 2025.

The company sells primarily to enterprise health plans, with Medicare Advantage plans as the principal buyer. The value proposition is anchored on closing the dementia care gap—approximately 40% of cases go undiagnosed—by enabling population health screening that captures RAF adjustments and reduces downstream care costs. Secondary buyers include healthcare providers, particularly primary care physicians who handle 80% of dementia diagnoses but lack time for thorough evaluations. Named enterprise relationships include Humana, Mayo Clinic, Johns Hopkins Medicine, and the National Institute on Aging. Pricing is quote-based, recurring, and enterprise-tendered. In 2024, SPARK Neuro launched Spark Predict, a separate claims intelligence product that extends its data assets into AI-powered natural language data querying.

SPARK Neuro is a privately held, venture-backed company headquartered at 224 W 35th St, New York. It has raised approximately $35M+ in cumulative funding across multiple rounds, including a $13.5M Series A in October 2024. The leadership team combines clinical and commercial depth, including Founder & CEO Spencer Gerrol, President & COO Marinela Gombosev (scaled a neurodiagnostic device to 450 clinics), CSO Harry Leider (former Walgreens CMO), and Medical Director Richard Caselli (former Mayo Clinic Department of Neurology Chair with 300+ publications).

Short descriptiontext

SPARK Neuro is an FDA-cleared EEG-based dementia diagnostic platform serving Medicare Advantage health plans and healthcare providers. Its SPARK Scan uses proprietary machine learning and fractal signal processing to detect and differentiate dementia causes with over 90% accuracy, closing a major care gap.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersLos Angeles, United States
HQ citystring
Los Angeles
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
EEG dementia screening, neurological diagnostics, Alzheimer's detection, cognitive assessment platform, claims intelligence analytics
Industry4 codes
PRIMARYHLAHACAE
Neurological Monitoring (EEG, Seizure/Sleep/Neuro Wearables)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Patient Monitoring, Wearables & Remote Diagnostics
SECONDARYHLACAOAM
Real-World Data (RWD) / Real-World Evidence (RWE) & Observational Research Platforms
Healthcare & Life Sciences/Digital Health & Health IT/Clinical Trials & Research Informatics (eCOA/ePRO/EDC)
SECONDARYHLADALAF
Dementia/Alzheimer’s Care Management & Behavioral Support
Healthcare & Life Sciences/Elder Care & Long-Term Care/Senior Care Coordination & Case Management (Geriatric Care Management)
SECONDARYHLAKAIAH
Cognitive & Behavioral Neurology (Dementia/Memory Disorders)
NAICS code1 code
  • Scientific Research and Development Services5417
SIC code1 code
  • Services-Commercial Physical & Biological Research8731
Product category
Neurological Diagnostics
Social media profiles3 records
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model2 records
1SPARK Scan Diagnostic Services
TypeSubscription Recurring
Description

EEG-based dementia screening services sold to health plans and healthcare providers. Revenue derived from per-test or subscription-based pricing models for population health screening programs.

sparkneuro.com
2Health Plan Contracts
TypeSubscription Recurring
Description

B2B contracts with Medicare Advantage plans and health insurers to provide dementia screening services for their member populations, addressing underdiagnosis problems and RAF adjustment opportunities.

sparkneuro.com
Marketing channels7 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components1 value
Technology or R&D
Pricing details1 tier
1Enterprise health plan pricing (quote-based)
ModelSubscriptionBilling cadenceAnnual
Notes

No specific pricing tiers publicly available. Company operates through direct sales with health plans and healthcare systems. Contact page invites inquiries for demos and pricing information.

sparkneuro.com
GTM typeB2B
B2B
Offering typeSoftware
Software
Brand1 of 2 records shown
1Spark Predict
Description

AI-powered data intelligence platform built from the claims intelligence engine behind SPARK Neuro, allowing users to ask their data questions and get answers in seconds.

sparkneuro.com
+1 more record
Core offering1 text field

Spark Neuro sells the SPARK Scan, an FDA-cleared EEG-based dementia screening tool that uses a proprietary machine-learning platform and patent-pending Fractal Dimension Distributions to detect and differentiate causes of dementia (Alzheimer's, Parkinson's, Dementia with Lewy Bodies). The company also offers Spark Predict, a claims intelligence platform that lets users query data using natural language. Both products are sold primarily to Medicare Advantage health plans, health insurers, and large healthcare systems for population-level dementia screening and care planning.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 6 values shown
  • 90%+ disease classification accuracy (vs 56% for alternatives)
+5 more records
Product overview1 text field

SPARK Neuro offers a dementia diagnosis platform centered on the SPARK Scan, an FDA-cleared EEG-based screening tool for early dementia detection. The platform is built on a proprietary machine-learning engine that analyzes brain signals to classify and differentiate dementia causes (Alzheimer's, Parkinson's, Dementia with Lewy Bodies). Supporting offerings include Spark Predict for claims data querying and a portfolio of white papers covering the SPARK Scan methodology, health outcomes, and Medicare Advantage applications.

Scale indicator13 records

Each record includes

Type, Value, Description, Source

Partnership4 partners
Strategic tierCoreTypeOthers
Description

Healthcare partner displayed on SPARK Neuro's homepage. Humana is a major health insurance company, suggesting a commercial relationship for dementia care gap solutions.

Strategic tierCoreTypeOthers
Description

Healthcare system partner displayed on homepage. Mayo Clinic is a premier medical institution, indicating clinical validation or collaboration in dementia diagnosis.

Strategic tierCoreTypeOthers
Description

Healthcare system partner displayed on homepage. Johns Hopkins is a leading medical institution, suggesting clinical validation or research collaboration.

4National Institute on Aging
Strategic tierCoreTypeOthers
Description

Government research partner displayed on homepage. NIoH is part of NIH, suggesting research collaboration and validation in dementia/brain health.

sparkneuro.com
Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

C2N Diagnostics markets PrecivityAD, a blood-based Alzheimer's diagnostic test with comparable accuracy claims and payer-facing commercialization. Both companies target early dementia detection with clinical-grade accuracy and pursue health plan and health system partnerships.

TypeDirect peer
Description

Quanterix operates a high-sensitivity biomarker platform (Simoa) used for blood-based neurodegenerative disease detection and pharma research. It directly competes for the same payer and pharmaceutical customer wallet that SPARK targets, with overlapping indications in Alzheimer's and related dementias.

TypeDirect peer
Description

Linus Health offers a digital cognitive assessment platform combining tablet-based tests with AI analytics for early dementia detection. Both SPARK and Linus compete for health system and payer contracts focused on closing the dementia diagnosis gap.

4Cognito Therapeutics
TypeDirect peer
Description

Cognito Therapeutics develops neurotechnology-based therapies and diagnostics for neurodegenerative disease. It overlaps with SPARK in brain-signal-based measurement of cognitive decline and shares a similar EEG/neurophysiology technology foundation.

TypeDirect peer
Description

Altoida uses AI-driven digital biomarkers (AR-based cognitive assessments on smartphones/tablets) for early Alzheimer's detection. Both companies pursue FDA-cleared, non-invasive, task-based alternatives to traditional cognitive screening and target similar payer and pharma customers.

TypeDirect peer
Description

BrainCheck provides a digital cognitive assessment platform used by clinicians and health systems for dementia screening. It competes in the same workflow-replacement position versus paper-based screeners that SPARK Scan targets.

TypeDirect peer
Description

Neurotrack develops digital cognitive assessment tools for early detection and monitoring of cognitive decline. Both companies target health plans, health systems, and pharmaceutical companies with non-invasive screening solutions.

TypeBroad incumbent
Description

Roche has commercialized Elecsys CSF and blood-based Alzheimer's biomarker assays with FDA breakthrough designation, and operates a global diagnostics infrastructure that dwarfs SPARK's. It represents the most significant incumbent threat in the payer-reimbursed Alzheimer's diagnostic category.

TypeEmerging player
Description

Cleveland Diagnostics is developing blood-based diagnostics for prostate and other cancers and is expanding into neurodegenerative disease biomarkers. It is an emerging competitor in the same blood-based diagnostic category that could pressure EEG-based screening workflows.

TypeBroad incumbent
Description

Eli Lilly is both a leader in disease-modifying Alzheimer's therapeutics (Kisunla/donanemab) and an active developer of companion diagnostics. Its scale and integrated therapeutic-diagnostic roadmap represent a long-term strategic incumbent for any early-detection company, including SPARK.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers4 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI capability3 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature6 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles7 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance1 record

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds2 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors11 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Spark Neuro

Neurological Diagnosticssparkneuro.com

SPARK Neuro is an FDA-cleared EEG-based dementia diagnostic platform serving Medicare Advantage health plans and healthcare providers. Its SPARK Scan uses proprietary machine learning and fractal signal processing to detect and differentiate dementia causes with over 90% accuracy, closing a major care gap.

What Spark Neuro does

SPARK Neuro is a New York-based neuroscience company founded in 2017 that has pivoted from its original neuromarketing focus to clinical dementia diagnosis. Its core product, SPARK Scan, is an FDA-cleared EEG-based screening tool that uses a proprietary machine-learning platform built on patent-pending Fractal Dimension Distributions (FDD) signal processing to detect and differentiate between dementia-causing diseases. The technology achieves 90%+ disease classification accuracy, 82% screening true positive rate, 96% accuracy in detecting Alzheimer's, and 80%+ accuracy in differentiating between Alzheimer's, Parkinson's, and Dementia with Lewy Bodies. SPARK Neuro has accumulated 900+ EEG datasets since 2021, secured 2 FDA clearances, and supported 5 clinical trials as of 2025.

The company sells primarily to enterprise health plans, with Medicare Advantage plans as the principal buyer. The value proposition is anchored on closing the dementia care gap—approximately 40% of cases go undiagnosed—by enabling population health screening that captures RAF adjustments and reduces downstream care costs. Secondary buyers include healthcare providers, particularly primary care physicians who handle 80% of dementia diagnoses but lack time for thorough evaluations. Named enterprise relationships include Humana, Mayo Clinic, Johns Hopkins Medicine, and the National Institute on Aging. Pricing is quote-based, recurring, and enterprise-tendered. In 2024, SPARK Neuro launched Spark Predict, a separate claims intelligence product that extends its data assets into AI-powered natural language data querying.

SPARK Neuro is a privately held, venture-backed company headquartered at 224 W 35th St, New York. It has raised approximately $35M+ in cumulative funding across multiple rounds, including a $13.5M Series A in October 2024. The leadership team combines clinical and commercial depth, including Founder & CEO Spencer Gerrol, President & COO Marinela Gombosev (scaled a neurodiagnostic device to 450 clinics), CSO Harry Leider (former Walgreens CMO), and Medical Director Richard Caselli (former Mayo Clinic Department of Neurology Chair with 300+ publications).

Spark Neuro firmographics

Firmographics
Name
Spark Neuro
Legal name
SPARK Neuro
Website
https://sparkneuro.com
Company type
Private
Founded year
2017
Operating status
Operating
Headcount range
11–50 employees
Short description
SPARK Neuro is an FDA-cleared EEG-based dementia diagnostic platform serving Medicare Advantage health plans and healthcare providers. Its SPARK Scan uses proprietary machine learning and fractal signal processing to detect and differentiate dementia causes with over 90% accuracy, closing a major care gap.
Ownership category
akta.pro rank

Spark Neuro industry classification

Industry
Product category
Neurological Diagnostics
NAICS
Scientific Research and Development Services (5417)
SIC
Services-Commercial Physical & Biological Research (8731)
akta.pro industry
PRIMARYHLAHACAE
Neurological Monitoring (EEG, Seizure/Sleep/Neuro Wearables)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Patient Monitoring, Wearables & Remote Diagnostics
SECONDARYHLACAOAM
Real-World Data (RWD) / Real-World Evidence (RWE) & Observational Research Platforms
Healthcare & Life Sciences/Digital Health & Health IT/Clinical Trials & Research Informatics (eCOA/ePRO/EDC)
SECONDARYHLADALAF
Dementia/Alzheimer’s Care Management & Behavioral Support
Healthcare & Life Sciences/Elder Care & Long-Term Care/Senior Care Coordination & Case Management (Geriatric Care Management)
SECONDARYHLAKAIAH
Cognitive & Behavioral Neurology (Dementia/Memory Disorders)

Keywords

  • EEG dementia screening
  • Neurological diagnostics
  • Alzheimer's detection
  • Cognitive assessment platform
  • Claims intelligence analytics

Where Spark Neuro is headquartered

Location

Headquarters

HQ city
Los Angeles
HQ country
United States
HQ region
North America

Offices1 record

Markets served

Spark Neuro business model

Business model
GTM type
B2B
Offering type
Software
Cost components
Technology or R&D

Revenue model

  1. SPARK Scan Diagnostic Services: EEG-based dementia screening services sold to health plans and healthcare providers. Revenue derived from per-test or subscription-based pricing models for population health screening programs.
  2. Health Plan Contracts: B2B contracts with Medicare Advantage plans and health insurers to provide dementia screening services for their member populations, addressing underdiagnosis problems and RAF adjustment opportunities.

Pricing tiers

ModelBillingPrice
SubscriptionAnnualEnterprise health plan pricing (quote-based)

Go-to-market motion2 records

Distribution channels1 record

Marketing channels7 records

Spark Neuro product offering

Product offering

Core offering

Spark Neuro sells the SPARK Scan, an FDA-cleared EEG-based dementia screening tool that uses a proprietary machine-learning platform and patent-pending Fractal Dimension Distributions to detect and differentiate causes of dementia (Alzheimer's, Parkinson's, Dementia with Lewy Bodies). The company also offers Spark Predict, a claims intelligence platform that lets users query data using natural language. Both products are sold primarily to Medicare Advantage health plans, health insurers, and large healthcare systems for population-level dementia screening and care planning.

Product overview

SPARK Neuro offers a dementia diagnosis platform centered on the SPARK Scan, an FDA-cleared EEG-based screening tool for early dementia detection. The platform is built on a proprietary machine-learning engine that analyzes brain signals to classify and differentiate dementia causes (Alzheimer's, Parkinson's, Dementia with Lewy Bodies). Supporting offerings include Spark Predict for claims data querying and a portfolio of white papers covering the SPARK Scan methodology, health outcomes, and Medicare Advantage applications.

Differentiator

Problem solved

Functional benefit

Brands

  • Spark Predict: AI-powered data intelligence platform built from the claims intelligence engine behind SPARK Neuro, allowing users to ask their data questions and get answers in seconds.
  • SPARK Scan

Quantifiable outcome

  • 90%+ disease classification accuracy (vs 56% for alternatives)
  • +5 more outcomes

Companies that use Spark Neuro

Customer profile

Named customers4 records

Segments3 records

Ideal customer profiles2 records

Spark Neuro technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

AI capability3 records

Feature6 records

Spark Neuro partnerships and signals

Strategic signal

Partnerships

Four partnerships are on record, tiered core.

  • HumanacoreOthersHealthcare partner displayed on SPARK Neuro's homepage. Humana is a major health insurance company, suggesting a commercial relationship for dementia care gap solutions.
  • Mayo CliniccoreOthersHealthcare system partner displayed on homepage. Mayo Clinic is a premier medical institution, indicating clinical validation or collaboration in dementia diagnosis.
  • Johns Hopkins MedicinecoreOthersHealthcare system partner displayed on homepage. Johns Hopkins is a leading medical institution, suggesting clinical validation or research collaboration.
  • National Institute on AgingcoreOthersGovernment research partner displayed on homepage. NIoH is part of NIH, suggesting research collaboration and validation in dementia/brain health.

Scale indicators13 records

Recent moves6 records

Expansion highlights5 records

Spark Neuro competitors and assessment

Company assessment

Direct peers

  • C2N Diagnostics: C2N Diagnostics markets PrecivityAD, a blood-based Alzheimer's diagnostic test with comparable accuracy claims and payer-facing commercialization. Both companies target early dementia detection with clinical-grade accuracy and pursue health plan and health system partnerships.
  • Quanterix: Quanterix operates a high-sensitivity biomarker platform (Simoa) used for blood-based neurodegenerative disease detection and pharma research. It directly competes for the same payer and pharmaceutical customer wallet that SPARK targets, with overlapping indications in Alzheimer's and related dementias.
  • Linus Health: Linus Health offers a digital cognitive assessment platform combining tablet-based tests with AI analytics for early dementia detection. Both SPARK and Linus compete for health system and payer contracts focused on closing the dementia diagnosis gap.
  • Cognito Therapeutics: Cognito Therapeutics develops neurotechnology-based therapies and diagnostics for neurodegenerative disease. It overlaps with SPARK in brain-signal-based measurement of cognitive decline and shares a similar EEG/neurophysiology technology foundation.
  • Altoida: Altoida uses AI-driven digital biomarkers (AR-based cognitive assessments on smartphones/tablets) for early Alzheimer's detection. Both companies pursue FDA-cleared, non-invasive, task-based alternatives to traditional cognitive screening and target similar payer and pharma customers.
  • BrainCheck: BrainCheck provides a digital cognitive assessment platform used by clinicians and health systems for dementia screening. It competes in the same workflow-replacement position versus paper-based screeners that SPARK Scan targets.
  • Neurotrack: Neurotrack develops digital cognitive assessment tools for early detection and monitoring of cognitive decline. Both companies target health plans, health systems, and pharmaceutical companies with non-invasive screening solutions.

Broad incumbents

  • Roche (Elecsys AD diagnostics): Roche has commercialized Elecsys CSF and blood-based Alzheimer's biomarker assays with FDA breakthrough designation, and operates a global diagnostics infrastructure that dwarfs SPARK's. It represents the most significant incumbent threat in the payer-reimbursed Alzheimer's diagnostic category.
  • Eli Lilly (Alzheimer's diagnostics and therapeutics): Eli Lilly is both a leader in disease-modifying Alzheimer's therapeutics (Kisunla/donanemab) and an active developer of companion diagnostics. Its scale and integrated therapeutic-diagnostic roadmap represent a long-term strategic incumbent for any early-detection company, including SPARK.

Emerging players

  • Cleveland Diagnostics: Cleveland Diagnostics is developing blood-based diagnostics for prostate and other cancers and is expanding into neurodegenerative disease biomarkers. It is an emerging competitor in the same blood-based diagnostic category that could pressure EEG-based screening workflows.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

Spark Neuro social profiles

Digital presence

Spark Neuro compliance and trust

Trust signal

Compliance1 record

Spark Neuro financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Spark Neuro leadership team

Management profile

Number of profiles

Profiles7 records

Spark Neuro funding detail

Funding detail

Funding overview

Funding rounds2 records

Investors11 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Spark Neuro M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Spark Neuro

What does Spark Neuro do?

Spark Neuro sells the SPARK Scan, an FDA-cleared EEG-based dementia screening tool that uses a proprietary machine-learning platform and patent-pending Fractal Dimension Distributions to detect and differentiate causes of dementia (Alzheimer's, Parkinson's, Dementia with Lewy Bodies). The company also offers Spark Predict, a claims intelligence platform that lets users query data using natural language. Both products are sold primarily to Medicare Advantage health plans, health insurers, and large healthcare systems for population-level dementia screening and care planning.

Is Spark Neuro a public or private company?

Spark Neuro is a private company. It is classified as venture growth investor backed and is currently operating.

When was Spark Neuro founded?

Spark Neuro was founded in 2017. It employs 11 to 50 people.

Where is Spark Neuro based?

Spark Neuro is headquartered in Los Angeles, United States, in the North America region.

How does Spark Neuro make money?

Two revenue lines are on record. SPARK Scan Diagnostic Services are the primary driver. The others are health Plan Contracts.

Who are Spark Neuro's main competitors?

Direct peers on record are C2N Diagnostics, Quanterix, Linus Health, Cognito Therapeutics, Altoida, BrainCheck and Neurotrack. Broad incumbents are Roche (Elecsys AD diagnostics) and Eli Lilly (Alzheimer's diagnostics and therapeutics). Cleveland Diagnostics is listed as an emerging player.

Does Spark Neuro have an API?

No public API is recorded for Spark Neuro.

What industry is Spark Neuro in?

Spark Neuro's product category is Neurological Diagnostics. Its primary akta.pro industry code is HLAHACAE, Neurological Monitoring (EEG, Seizure/Sleep/Neuro Wearables), with a secondary code of HLACAOAM, Real-World Data (RWD) / Real-World Evidence (RWE) & Observational Research Platforms. Its NAICS code is 5417 and its SIC code is 8731.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
PR NewswireLongtime Mayo Clinic Neurologist Dr. Richard J. Caselli Joins SPARK Neuro as Medical DirectorSPARK Neuro, a brain health diagnostics company, announced the appointment of Dr. Richard J. Caselli as its Medical Director, hiring him away from the Mayo Clinic where he spent 35 years as a neurologist. Dr. Caselli previously collaborated with SPARK Neuro on NIH-funded research that contributed to the company's FDA-cleared AI-enabled EEG brain scan technology for dementia assessment. The appointment aims to advance neurodiagnostics and address the estimated 40% of dementia cases that currently go undiagnosed.The Trade DeskHow to take advantage of context-based strategies in your next campaignsThe article provides a guide on implementing context-based advertising strategies, which deliver relevant ads by analyzing page content rather than user behavior. It highlights that contextual targeting can generate 43 percent more engagement and twice the ad recall according to SPARK Neuro research. The text outlines best practices for using standard and custom categories across various ad formats like native and video.The New YorkerThe Neuroscience of Picking a Presidential CandidateSPARK Neuro, a neuromarketing firm, tested voters' subconscious reactions to presidential candidates using brain waves and physiological signals. Its 2016 study found many undecided voters had strong emotional responses to Trump, while a 2020 debate test showed Elizabeth Warren and Pete Buttigieg engaged more than Joe Biden. The company has not worked for a candidate but is exploring political applications.PR NewswireBiometric Study Reveals Link Between Emotions in Entertainment Content and Brand ValueMirriad and SPARK Neuro published a neural and biometric study examining how emotions in entertainment content affect brand value, finding that specific emotions drive measurable increases in consumer willingness to pay. The two-phase study, involving 900 online participants and 50 in a neuroanalytics lab, revealed that sadness drove a 17% valuation lift for food/drink products, disgust a 22% lift for cleaning products, and anticipation a 7% lift for automotive brands. The research was presented at Advertising Week New York on September 23, 2019, with the companies promoting the 'emotional carryover' effect as a new approach for targeted advertising in content.PR NewswireBiometric Study Reveals Link Between Emotions in Entertainment Content and Brand ValueMirriad and SPARK Neuro conducted a biometric study revealing that specific emotions in entertainment content, such as sadness for food products and disgust for cleaning items, significantly increase brand value. The research demonstrated that inserting ads into emotionally charged scenes resulted in valuation lifts ranging from 6% to 27% across tested categories including potato chips, Lysol wipes, and Jeep Wrangler. These findings were presented at Advertising Week New York to illustrate how emotional context can enhance advertising effectiveness.Fast CompanyThis breakthrough technology measures your attention and emotional response to contentSPARK Neuro is utilizing neuroanalytics technology to measure human attention and emotional responses to content with second-by-second precision, aiming to provide more accurate data than traditional focus groups. The company is initially applying this technology to optimize advertising and movie trailers, with plans to expand into sectors such as politics and counter-terrorism.PR NewswireSPARK Neuro Catapults Neuroanalytics Industry into New Frontier with Investments in Advanced TechnologyNeuroanalytics startup SPARK Neuro announced significant technological advancements and expansion plans, including the adoption of functional near-infrared spectroscopy (fNIRS) to enhance audience engagement research. The company is opening offices in Tokyo, Washington D.C., and Europe while securing a Department of Defense grant for counter-terrorism research ahead of the 2020 election. These moves follow a $13.5 million Series A funding round led by Thiel Capital.GristWhy your brain doesn’t register the words ‘climate change’SPARK Neuro's experiment with 120 participants found 'climate crisis' elicited a 60% greater emotional response than 'climate change' or 'global warming'. The phrase 'environmental destruction' triggered too much emotion among Republicans, while 'climate crisis' struck a balance. Further testing is needed to determine the best messaging.